Hudson Bay Capital Management LP Macrogenics Inc Transaction History

Hudson Bay Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $2.6 Million - $14.6 Million	786,394 Added 604.3%	916,527 $3.9 Million
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $790,783 - $1.74 Million	80,940 Added 164.54%	130,133 $1.92 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $220,384 - $497,341	49,193 New	49,193 $473,000
Q4 2019 Feb 12, 2020	SELL	$7.95 - $12.27 $318,795 - $492,027	-40,100 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$12.44 - $17.48 $1,244 - $1,748	100 Added 0.25%	40,100 $512,000
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $872,051 - $1.18 Million	-60,100 Reduced 60.04%	40,000 $679,000
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $1.11 Million - $2.56 Million	100,100 New	100,100 $1.8 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.